Authors

  1. Aschenbrenner, Diane S. MS, RN

Abstract

* For the first time, a drug, tesamorelin (Egrifta), has been approved to treat HIV therapy-related lypodystrophy.

 

* Tesamorelin decreases abdominal fat, but it's not yet known whether the drug decreases the risk of cardiovascular disease or increases compliance with HIV therapy.

 

* Tesamorelin may cause significant changes in blood glucose levels, among other adverse effects.